Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Adenocarcinoma
/ drug therapy
Adult
Aged
Colorectal Neoplasms
/ drug therapy
Comorbidity
Drug Combinations
Female
Humans
Japan
/ epidemiology
Male
Middle Aged
Neoplasm Metastasis
Patient Selection
Phenylurea Compounds
/ therapeutic use
Progression-Free Survival
Pyridines
/ therapeutic use
Pyrrolidines
/ adverse effects
Retrospective Studies
Salvage Therapy
Survival Analysis
Thymine
/ adverse effects
Treatment Outcome
Trifluridine
/ adverse effects
Comorbidity
TAS-102
metastatic colorectal cancer
regorafenib
trifluridine/tipiracil
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
02
2021
revised:
24
02
2021
accepted:
25
02
2021
entrez:
4
4
2021
pubmed:
5
4
2021
medline:
10
4
2021
Statut:
ppublish
Résumé
In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear. The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities. Among the 27 patients who received trifluridine/tipiracil, many had comorbidities of deep venous thrombosis or hemorrhage. The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. The median overall survival was 7.7 months in 19 patients without subsequent regorafenib. Grade 3 or higher toxicities were found in 51% of patients. No treatment discontinuation because of comorbidities was observed. Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear.
PATIENTS AND METHODS
METHODS
The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities.
RESULTS
RESULTS
Among the 27 patients who received trifluridine/tipiracil, many had comorbidities of deep venous thrombosis or hemorrhage. The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. The median overall survival was 7.7 months in 19 patients without subsequent regorafenib. Grade 3 or higher toxicities were found in 51% of patients. No treatment discontinuation because of comorbidities was observed.
CONCLUSION
CONCLUSIONS
Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib.
Identifiants
pubmed: 33813435
pii: 41/4/2203
doi: 10.21873/anticanres.14996
doi:
Substances chimiques
Drug Combinations
0
Phenylurea Compounds
0
Pyridines
0
Pyrrolidines
0
trifluridine tipiracil drug combination
0
regorafenib
24T2A1DOYB
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2203-2207Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.